Telix Pharmaceuticals Limited (ASX:TLX)


right-arrow Created with Sketch. -0.03 (-0.45%)
MCAP $1.890B
Last trade 16.10pm 30/11/2021 20mins delayed

Latest Announcements

16/11/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
02/11/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
21/10/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
21/10/2021TLXTelix Pharmaceuticals Limited
20/10/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
29/09/2021TLXTelix Pharmaceuticals Limited
29/09/2021TLXTelix Pharmaceuticals Limited
29/09/2021TLXTelix Pharmaceuticals Limited

Company Overview

Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The Company's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.

TLX in the news

Telix Pharmaceuticals (TLX) has received approval from the Australian drug watchdog for…
Telix Pharmaceuticals (TLX) pockets a research and development (R&D) tax refund of…
Telix Pharmaceuticals (TLX) sees its review period for its prostate cancer imaging…
Telix Pharmaceuticals (TLX) receives approval from the US Food and Drug Administration…

Search Previous Announcements